TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04867005

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Impact of a training program
Description: Measurement of the effectiveness of a training program based on the skills and knowledge learning on advance care planning. A 10 hours online course was administered to both arms through an online platform; the 6 hours face-to-face course was administered to each primary care team (5) included in this arm. The 6 hours course was split into 2 sessions of 3 hours each.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Impact of a training program
Description: Measurement of the effectiveness of a training program based on the skills and knowledge learning on advance care planning. A 10 hours online course was administered to both arms through an online platform; the 6 hours face-to-face course was administered to each primary care team (5) included in this arm. The 6 hours course was split into 2 sessions of 3 hours each.
Study: NCT01473914

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low dose: supplemental zinc, selenium and vitamin E
Description: 1. ZINC 25mg (AS ZINC SULFATE)~2. SELENIUM 50 mcg (AS SODIUM SELENITE)~3. VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard renal vitamin: B and C renal vitamin
Description: 1. BIOTIN 300 MCG~2. D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 10 MG~3. FOLIC ACID 1 MG~4. NIACINAMIDE 20 MG~5. VITAMIN B1 (THIAMINE MONONITRATE) 1.5 MG~6. VITAMIN B12(CYANOCOBALAMIN) 6 MCG~7. VITAMIN B2 (RIBOFLAVIN) 1.7 MG~8. VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG~9. VITAMIN C (ASCORBIC ACID) 100 MG~10. INERT FILLER (CORNSTARCH)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard renal vitamin: B and C renal vitamin
Description: 1. BIOTIN 300 MCG~2. D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 10 MG~3. FOLIC ACID 1 MG~4. NIACINAMIDE 20 MG~5. VITAMIN B1 (THIAMINE MONONITRATE) 1.5 MG~6. VITAMIN B12(CYANOCOBALAMIN) 6 MCG~7. VITAMIN B2 (RIBOFLAVIN) 1.7 MG~8. VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG~9. VITAMIN C (ASCORBIC ACID) 100 MG~10. INERT FILLER (CORNSTARCH)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard renal vitamin: B and C renal vitamin
Description: 1. BIOTIN 300 MCG~2. D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 10 MG~3. FOLIC ACID 1 MG~4. NIACINAMIDE 20 MG~5. VITAMIN B1 (THIAMINE MONONITRATE) 1.5 MG~6. VITAMIN B12(CYANOCOBALAMIN) 6 MCG~7. VITAMIN B2 (RIBOFLAVIN) 1.7 MG~8. VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG~9. VITAMIN C (ASCORBIC ACID) 100 MG~10. INERT FILLER (CORNSTARCH)
Study: NCT03035500

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Receive health education

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-term Follow-up
Description: Undergo long-term follow-up using survivorship care plan

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT01473914

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Medium dose: supplemental zinc, selenium and vitamin E
Description: 1. ZINC 50 mg (AS ZINC SULFATE)~2. SELENIUM 75 mcg (AS SODIUM SELENITE)~3. VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU
Study: NCT00795210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone
Description: Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth Hormone Releasing Hormone
Description: Tesamorelin (GHRH) 2mg SC QD x 2 weeks
Study: NCT01856348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Study: NCT05025904

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Real-time fMRI neurofeedback (rt-fMRI NFB)
Description: Real-time fMRI neurofeedback targeting control of the left medial prefrontal cortex. Participants continuously received visual feedback on the level of activity within the 2D region of interest corrected to the whole-slice brain volume activity. Up- and downregulation blocks were switched for better control.
Study: NCT04427761

Intervention type: BEHAVIORAL
Intervention: Measurement of Transitions in Cancer Scale (MOT-CA) Survey
Description: These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit) The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).

Intervention type: BEHAVIORAL
Intervention: Distress Thermometer Survey
Description: These surveys will take 5-10 minutes to complete at two time-points, T0 (baseline) and T1 (four to six weeks after baseline visit).The patient will again complete the DT and MOT-CA at a chemotherapy treatment or clinic visit, if possible, or via a telephone call with the principal investigator in the event that there are no in-person visits scheduled (Time 1).
Study: NCT03726697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tahneek
Description: A single dose of soft date containing glucose equivalent to 200mg/kg at 1 h after birth will be massaged into the buccal mucosa of the palate and cheek from right to left side, until the date paste is fully absorbed
Study: NCT05025904

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Сognitive behavioral therapy (CBT)
Description: A combination of individual and small-group cognitive behavioral therapy by an experienced medical psychologist and a psychiatrist.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EEG neurofeedback (EEG NFB)
Description: EEG neurofeedback targeting frontal alpha asymmetry index. Participants continuously received visual feedback on their frontal alpha asymmetry index. Up-regulation condition only was utilized.
Study: NCT00326118

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Haemophilus influenzae type b and meningococcal serogroup C (vaccine)
Description: One intramuscular dose at 12-18 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Priorix™
Description: One subcutaneous dose at 12-18 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Priorix™
Description: One subcutaneous dose at 12-18 months of age

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Hiberix™
Description: One intramuscular dose at 12-18 months of age.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningitec™
Description: One intramuscular dose at 12-18 months of age
Study: NCT03363724

Intervention type: OTHER
Intervention: HaGuide version 1.0 software module
Study: NCT04426188

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Heading series
Description: 10 headers from machine-projected soccer balls at standardized speeds

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Heading series
Description: 10 headers from machine-projected soccer balls at standardized speeds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging (MRI)
Description: Brain MRI before and after a series

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: Brain MRI before and after a series

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive computerized assessment
Description: Cognitive evaluation carried out with two computerized tools

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Cognitive computerized assessment
Description: Cognitive evaluation carried out with two computerized tools

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrophysiological records
Description: Electrophysiological recording of Motor Evoked Potentials consisting of the application of transcranial magnetic stimulations (TMS) and the collection of muscle activity by electromyogram (EMG)

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electrophysiological records
Description: Electrophysiological recording of Motor Evoked Potentials consisting of the application of transcranial magnetic stimulations (TMS) and the collection of muscle activity by electromyogram (EMG)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamometer
Description: Measure of the strength of the neck muscles using a dynamometer

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Dynamometer
Description: Measure of the strength of the neck muscles using a dynamometer
Study: NCT00098839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study: NCT02021019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Renal Denervation
Study: NCT01808508

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous positive airway pressure
Description: Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham or placebo continuous positive airway pressure
Description: Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
Study: NCT03829527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychotherapy
Description: Psychological intervention combining a standardized treatment manual with a smartphone application
Study: NCT00098839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epratuzumab
Description: Given IV
Study: NCT02585375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Preservative-free latanoprost 50µg/ml
Study: NCT01693016

Intervention type: DEVICE
Group type: OTHER
Intervention: non-invasive measurement of Hb

Intervention type: DEVICE
Group type: OTHER
Intervention: non-invasive measurement of Hb

Intervention type: PROCEDURE
Group type: OTHER
Intervention: taking blood samples

Intervention type: PROCEDURE
Group type: OTHER
Intervention: taking blood samples
Study: NCT02585375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Preserved latanoprost 0.005%
Study: NCT01465048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum sporozoites 2sites
Description: Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intradermal injection sites
Study: NCT01321879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telavancin
Description: 10 mg/kg by vein once daily for patients with a creatinine clearance of more than 50 ml/min, and a dose of 7.5 mg/kg once daily for patients with a creatinine clearance of 30-50 ml/min.
Study: NCT00780338

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assets Getting To Outcomes
Description: Face to Face Training Assets Getting To Outcomes Manuals Technical Assistance

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Assets Getting To Outcomes
Description: Face to Face Training Assets Getting To Outcomes Manuals Technical Assistance
Study: NCT04000139

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standardized anthocyanin-rich extract
Description: 3g of anthocyanin-rich extract taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3g of placebo taken daily as: 3 doses of 2x 500mg. Treatment duration 56 days (8 weeks).
Study: NCT00977093

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perfusion CMR for detection of coronary artery disease
Description: Perfusion CMR is performed during adenosine infusion for vasodilation (3 minutes of 0.14mg/kg/min IV) and injection of Gd-DTPA-BMA at 0.075mmol/kg IV.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perfusion cardiac magnetic resonance imaging
Description: Perfusion CMR with Gd-DTPA-BMA to detect coronary artery disease
Study: NCT01476137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2110183
Description: AKT inhibitor
Study: NCT01465048

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum sporozoites 1 site
Description: Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intramuscular injection sites

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasmodium falciparum sporozoites 1site
Description: Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 25,000 sporozoites, 50ulx2, 2 intramuscular injection sites
Study: NCT02980939

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iv fluid infusion
Description: Intravenous isotonic saline infusion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: iv fluid infusion
Description: Intravenous isotonic saline infusion
Study: NCT03296904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CLs++
Description: Familiarization/training with the customized combination of the CLs++ ortho-prosthesis modules
Study: NCT04045405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDR132L
Description: i.v. administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CDR132L
Description: i.v. administration
Study: NCT00098839

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: epratuzumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexrazoxane hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study: NCT03833284

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Participant Barriers to TVU Screening
Description: Workshops tailored toward patients to increase knowledge about TVU screening guidelines and benefits.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Barriers to TVU Screening
Description: Workshops tailored toward providers to increase knowledge about TVU screening guidelines and benefits.
Study: NCT03897972

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-personalised diet advice delivered via the eNutri app (control)
Description: Non-personalised dietary advice to improve food choices based on standard population guidelines delivered by the eNutri app and irrespective of the dietary intakes from the food frequency questionnaire (control group).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalised diet advice delivered via the eNutri app (intervention)
Description: Personalised dietary advice to improve food choices based on adherence to an 11-item diet quality score, which is determined by the eNutri app in response to the dietary intakes from the food frequency questionnaire (intervention group).
Study: NCT05329597

Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping is performed using the subjects' blood cells

Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping is performed using the subjects' blood cells

Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping is performed using the subjects' blood cells

Intervention type: GENETIC
Intervention: Genotyping
Description: Genotyping is performed using the subjects' blood cells
Study: NCT04935151

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: holmium laser enucleation of the prostate
Description: cystoscopic transurethral enucleation of the prostate using Holmium laser

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar resection of the prostate
Description: cystoscopic transurethral resection of the prostate using bipolar energy
Study: NCT01340976

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2787106
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2787106
Description: Administered IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2787106
Description: Administered IV.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron Supplementation
Description: Administered orally.
Study: NCT02897596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg/d 8 weeks
Description: Patients with 1b HCV genotype will be received treatment with Grazoprevir (100 mg) during 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg/d 8 weeks
Description: Patients with 1b HCV genotype will be received treatment with Elbasvir (50mg) during 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir 100 mg/d 12 weeks
Description: Patients with 1a or 4 HCV genotype will be received treatment with Grazoprevir (100 mg) during 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir 50 mg/d 12 weeks
Description: Patients with 1a or 4 HCV genotype will be received treatment with Elbasvir (50mg) during 12 weeks.
Study: NCT02567396

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT01015118

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparator to BIBF 1120
Study: NCT02567396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Given PO
Study: NCT01015118

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (standard chemo-therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBF 1120
Description: comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
Study: NCT03341052

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Diet
Description: The normal diet will consist of the participants' normal eating habits, and will be tracked by a food log. The participants will be on their normal diet during week 1 and week 3.
Study: NCT01015118

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (standard chemo-therapy)
Study: NCT03341052

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal Diet
Description: The normal diet will consist of the participants' normal eating habits, and will be tracked by a food log. The participants will be on their normal diet during week 1 and week 3.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Fat Diet
Description: The high fat diet will consist of 2700 kcal, 100g total fat (33%), 300mg cholesterol, 350g carbohydrates (52%), and 100g protein (15%). The participants will be on this diet during week 2.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High Fat Diet
Description: The high fat diet will consist of 2700 kcal, 100g total fat (33%), 300mg cholesterol, 350g carbohydrates (52%), and 100g protein (15%). The participants will be on this diet during week 2.
Study: NCT01015118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (standard chemo-therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (standard chemo-therapy)
Study: NCT03341052

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat Diet
Description: The low fat diet will consist of 1200 kcal, 26g fat (20%), 78mg cholesterol, 150g carbohydrates (50%), and 100g protein (30%). The participants will be on this diet during week 4.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat Diet
Description: The low fat diet will consist of 1200 kcal, 26g fat (20%), 78mg cholesterol, 150g carbohydrates (50%), and 100g protein (30%). The participants will be on this diet during week 4.
Study: NCT02953821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acthar Gel
Description: 1 mL (80 Units) given by a shot under the skin (via subcutaneous injection)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Gel
Description: 1 mL (0 Units) given by a shot under the skin (via subcutaneous injection)
Study: NCT00782210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744)
Description: Comparison of low and high doses on efficacy and safety in COPD patients

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olodaterol (BI1744)
Description: Comparison of low and high doses on efficacy and safety in COPD patients